IQV
Iqvia Holdings Inc. Health Care Services-Commercial Physical & Biological Research S&P 500Russell 3000
$267.33Close
$45.3BMarket cap
$156.66 – $279.3652-week range
Late-januaryNext report · estimated
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 83 · stronger than 83% of stocks over 12 months
- Near its high 4% below its 52-week high
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
4%
1wk
down 4.3%
price change
1mo
down 0.6%
price change
12-month return
up 23%
market up 11% ·
its own up 12%
F-score
—
— Not assessed
Altman Z″
1.13
Moderate risk
P/E
33.3×
price / earnings
PEG
7.09
P/E / EPS growth
P/B
7.0×
price / book
Earnings yield
up 3.8%
EBIT / enterprise value
Cheaper than
47%
of the market · around average
Revenue growth
up 6%
year on year
EPS growth
up 9%
latest quarter · +9 pts
Sales growth
up 8%
latest quarter · -1 pts
ROE
up 22%
return on equity
Free cash margin
up 13%
$2.1B FCF
D/E
2.14
long-term debt / equity
Net debt / EBITDA
3.6×
Interest cover
3.0×EBIT / interest
Trade setup
ATR%
3.4%
$9.07 a day · 2×ATR $249.18
RS
83 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
0.8×
vs 50-day average
Up/down volume
1.02
50 sessions
Implied move
—
no scheduled report
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- No restatement or impairment
- Equity positive
- Interest covered
- No material dilution
- Profits tracking cash
- Margins and revenue not shrinking
Last reported
Oct 27, 2026
Results reaction
Oct 27, 2026+1% vs market2 sessions after results
Options
$939,73839.1% IV · activity
Financials
- Net 8%
- Free cash 13%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $11.4B | $13.9B | $14.4B | $15.0B | $15.4B | $16.3B |
| Operating income | $731.0M | $1.4B | $1.8B | $2.0B | $2.2B | $2.2B |
| Net income | $279.0M | $966.0M | $1.1B | $1.4B | $1.4B | $1.4B |
| Net margin | 2% | 7% | 8% | 9% | 9% | 8% |
| Earnings per share | $1.43 | $4.95 | $5.72 | $7.29 | $7.49 | $7.84 |
| Free cash flow | $1.3B | $2.3B | $1.6B | $1.5B | $2.1B | $2.1B |
| Free cash margin | 12% | 17% | 11% | 10% | 14% | 13% |
| Cash | $1.8B | $1.4B | $1.2B | $1.4B | $1.7B | $2.0B |
| Long-term debt | $12.4B | $12.0B | $12.6B | $13.0B | $12.8B | $13.9B |
| Shareholders' equity | $6.0B | $6.0B | $5.8B | $6.1B | $6.1B | $6.5B |
| Shares outstanding | 191.20m | 190.60m | 185.70m | 181.50m | 176.10m | 169.60m |
What options price now
- Expected 1-month range The at-the-money straddle for the expiry nearest a month out, as a share of the price: the move, either way, the option market is pricing by then. The range is the price plus and minus that move; the stock ends inside it a little more often than not. Methodology
- $247 – $288 ±7.8% by Nov 20, 2026
- Swings expected vs recent The daily swings the options are priced for (implied volatility) against the swings the stock actually had over the last 20 sessions (realised volatility). Bigger means options charge for more movement than the stock has been delivering; smaller, less. On a contract row, that contract's own implied volatility over the stock's realised. Methodology
- Bigger 39.1% priced · 29.1% recent
- Next month vs later At-the-money implied volatility for 8-45 day expiries over 46-90 day ones: whether options price the coming month as choppier or calmer than the two after it. Ahead of a report it usually reads choppier, and the extra comes out once the report is out. Methodology
- Choppier
- Crash protection What options that pay off in a fall cost against options that pay off in a rise (the 25-delta skew), compared with this company's own normal - the median of its stored nightly readings, once there are 20 - and with five sessions ago. Protection costs a little more than upside on most shares. More than usual means readers of the chain are paying up to insure against a drop; it does not say which way the stock will go. Methodology
- past week: costs less
Positioning
- Premium traded
- $939,738 calls $354,398 · puts $585,340 · latest session
- 1.65× +1.25 over the week
- Open interest added The change over five sessions in option positions left open overnight, calls and puts. A rise means positions were added. It cannot say whether they were bought or sold, so more calls is not a vote for a rise: a call is as often sold against shares already held. Methodology
- calls +1.54k · puts +1.22k past week
For options traders: ATM IV 39.1% (-6.6% 1w) · 1m ÷ 3m IV 1.09 · 25Δ skew 1.6 pts · Net GEX $887,950
Most traded contracts
No contract passed the liquidity filters this week.
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 27, 2026 | Quarterly ↗ | Sep 30, 2026 | 27d |
| Jul 28, 2026 | Quarterly ↗ | Jun 30, 2026 | 28d |
| May 5, 2026 | Quarterly ↗ | Mar 31, 2026 | 35d |
| Feb 17, 2026 | Annual ↗ | Dec 31, 2025 | 48d |
| Oct 28, 2025 | Quarterly ↗ | Sep 30, 2025 | 28d |
| Jul 22, 2025 | Quarterly ↗ | Jun 30, 2025 | 22d |
| May 6, 2025 | Quarterly ↗ | Mar 31, 2025 | 36d |
| Feb 13, 2025 | Annual ↗ | Dec 31, 2024 | 44d |
| Oct 31, 2024 | Quarterly ↗ | Sep 30, 2024 | 31d |
| Jul 22, 2024 | Quarterly ↗ | Jun 30, 2024 | 22d |
| May 2, 2024 | Quarterly ↗ | Mar 31, 2024 | 32d |
| Feb 15, 2024 | Annual ↗ | Dec 31, 2023 | 46d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 27, 2026 | Results ↗ |
| Sep 23, 2026 | Material agreement · New obligation ↗ |
| Sep 9, 2026 | Other events ↗ |
| Jul 28, 2026 | Results ↗ |
| Jun 11, 2026 | Material agreement · New obligation ↗ |
| Jun 4, 2026 | Other events ↗ |
| Jun 3, 2026 | Other events ↗ |
| May 7, 2026 | Other events ↗ |
| May 5, 2026 | Results ↗ |
| Apr 23, 2026 | Director or officer change · Shareholder vote ↗ |
| Feb 5, 2026 | Results ↗ |
| Dec 9, 2025 | Material agreement · New obligation ↗ |